FDA grants Orphan Drug status for Shift’s lead compound for SMA

Shift’s E1V1.11 drug compound to treat Spinal Muscular Atrophy (SMA) granted Orphan Drug Status by FDA. Overland Park: The Food and Drug Administration (FDA) granted orphan drug designation for Shift Pharmaceutical’s lead drug compound to … Continue reading FDA grants Orphan Drug status for Shift’s lead compound for SMA